Supplementary Table 1 from A Phase I Trial of AT9283 (a Selective Inhibitor of Aurora Kinases) in Children and Adolescents with Solid Tumors: A Cancer Research UK Study

Autor: Darren Hargrave, Murray Yule, Melanie J. Griffin, Alan V. Boddy, John F. Lyons, Ana Rodriguez, Victoria Lock, Shamim Kazmi-Stokes, Philip Ross, Gary Acton, Sarah E.R. Halford, Guy Makin, Quentin Campbell-Hewson, Martin Elliott, Bruce Morland, Andrew D.J. Pearson, Lynley V. Marshall, Lucas Moreno
Rok vydání: 2023
DOI: 10.1158/1078-0432.22460574
Popis: Supplementary Table 1. Summary of pharmacodynamic changes observed in paired skin punch biopsies. Skin punch biopsies were optional until a dose limiting toxicity was found (11.5 mg/m2/day) when they were mandated. Inhibition of pHH3 (substrate for Aurora kinase B) can be observed in the majority of patients from the 11.5 mg/m2/day dose level. Decreases in Ki67 can be observed from the 18.5 mg/m2/day dose level.
Databáze: OpenAIRE